Last reviewed · How we verify
abciximab intravenously
abciximab intravenously is a GP IIb/IIIa inhibitor Small molecule drug developed by University of Leipzig. It is currently in Phase 3 development for Acute coronary syndrome, Percutaneous coronary intervention.
Abciximab inhibits platelet aggregation by binding to the glycoprotein IIb/IIIa receptor.
Abciximab inhibits platelet aggregation by binding to the glycoprotein IIb/IIIa receptor. Used for Acute coronary syndrome, Percutaneous coronary intervention.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | abciximab intravenously |
|---|---|
| Sponsor | University of Leipzig |
| Drug class | GP IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This prevents platelet activation and aggregation, thereby reducing thrombus formation. Abciximab is a monoclonal antibody that binds to the glycoprotein IIb/IIIa receptor on platelets, blocking the binding of fibrinogen and other ligands, which are essential for platelet aggregation.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention
Common side effects
- Thrombocytopenia
- Bleeding
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- abciximab intravenously CI brief — competitive landscape report
- abciximab intravenously updates RSS · CI watch RSS
- University of Leipzig portfolio CI
Frequently asked questions about abciximab intravenously
What is abciximab intravenously?
How does abciximab intravenously work?
What is abciximab intravenously used for?
Who makes abciximab intravenously?
What drug class is abciximab intravenously in?
What development phase is abciximab intravenously in?
What are the side effects of abciximab intravenously?
What does abciximab intravenously target?
Related
- Drug class: All GP IIb/IIIa inhibitor drugs
- Target: All drugs targeting Glycoprotein IIb/IIIa receptor
- Manufacturer: University of Leipzig — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Percutaneous coronary intervention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing